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Abstract: Type 2 diabetes is a chronic disease occurring in ever increasing numbers worldwide. 
It contributes significantly to the cost of health globally; however, its management remains in 
the most part less than optimal. Patients must be empowered to self-manage their disease, and 
they do this in partnership with health care professionals. Whilst the traditional role of the 
pharmacist has been centered around the supply of medicines and patient counseling, there is 
an evergrowing body of evidence that pharmacists, through a range of extended services, may 
contribute positively to the clinical and humanistic outcomes of those with diabetes. Further, 
these services can be delivered cost-effectively. This paper provides a review of the current 
evidence supporting the role of pharmacists in diabetes care, whilst providing a commentary 
of the future roles of pharmacists in this area.
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Introduction
Diabetes mellitus (“diabetes”) is one of the fastest growing chronic diseases worldwide, 
and is associated with significant morbidity, mortality, and health care costs. Diabetes 
is characterized by high levels of glucose in the blood (hyperglycemia). There are three 
main types of diabetes:
•	 Type 1 diabetes mellitus (T1DM) in which there is an absolute deficiency in insulin 
production. This disease can occur at any age, although it mostly occurs in children 
and young adults.1
•	 Type 2 diabetes mellitus (T2DM) which is associated with insulin resistance, with 
an initial increase in insulin secretion, however over time, beta cell death and insulin 
insufficiency. Although T2DM mainly occurs in people aged over 40 years old, the 
disease is also becoming increasingly prevalent in the younger age group.2,3
•	 Gestational diabetes which occurs during pregnancy. The condition usually disap-
pears once the baby is born; however, a history of gestational diabetes increases a 
woman’s risk of developing T2DM later in life.1
The statistics related to diabetes mellitus globally are alarming. The International 
Diabetes Federation (IDF) Diabetes Atlas, Seventh Edition, 2015, provides the following 
estimates: one in 11 adults have diabetes (416 million), nearly half (46.5%) of adults 
with diabetes are undiagnosed, one in seven births are affected by gestational diabetes, 
542,000 children have type 1 diabetes, and a person dies from diabetes every 6 seconds.4 
Further, the IDF estimates that by 2040, one in 10 adults (642 million) will have diabetes.4
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Of those people with diabetes, three quarters (75%) live 
in low- and middle-income countries.4 The Western Pacific 
region (which includes Australia) has 37% of all adults living 
with diabetes. This includes 100 million people in the People’s 
Republic of China (ranked highest in number of people with 
diabetes), 10 million people in Indonesia (seventh highest), 
and 7.2 million in Japan (ninth highest). Also included in this 
region is the country with the highest prevalence of diabetes 
the Pacific Island nation of Tokelau where 30% of the adult 
population has diabetes. Globally, Cambodia has the lowest 
prevalence of diabetes at 3%.4
T2DM is the greatest contributor to the burden of dia-
betes globally accounting for up to 90% of people with 
diabetes worldwide.4 Further, its prevalence is increasing in 
all countries around the world. This increase has paralleled 
the global epidemic of obesity. It is estimated that since 
1980 worldwide, obesity has nearly doubled. In 2008, it was 
estimated that there were 1.4 billion adults (35% of those 
20 years or older) who were overweight, of which over half 
a billion (11%) were obese.5 Importantly, it is reported that 
being overweight or obese contributes significantly to the 
burden of diabetes (44%), ischemic heart disease (23%), and 
certain cancers (range 7%–41%).5 Yet, obesity is preventable, 
and strategies to prevent diabetes and cardiovascular disease 
both include the common goal to optimize peoples’ weight 
through diet and exercise.
Adults with diabetes have a two- to threefold increased 
risk of suffering a heart attack or stroke compared to those 
without diabetes.6 The microvascular complications of 
diabetes mellitus make it the leading cause of preventable 
blindness, renal disease, and amputation in developed 
countries.6–8 These complications have dramatic implica-
tions for health care costs, with the total annual cost impact 
of diabetes in Australia estimated to be at $14.6 billion,9 
whilst globally, it is estimated to account for 12% of the 
global health expenditure (US$673 billion).4 By 2040, it is 
estimated that the proportion of global health expenditure 
will exceed US$802 billion.4
Optimizing therapy in patients with diabetes is a difficult 
clinical task requiring considerable patient education and 
motivation. The goal is to improve glycemic control without 
adverse bodyweight gain or hypoglycemia, and with a posi-
tive or neutral effect on lipid levels and blood pressure. Proper 
drug selection involves identifying the drug that is most likely 
to improve control and least likely to cause interactions, 
and adverse effect or adherence problems. Consequently, it 
has the potential to change patients’ futures and health care 
systems’ costs.10
Pharmacists represent the third largest health profession 
in the world11 after doctors and nurses. Most pharmacists 
work in the community with a smaller proportion in hospital 
pharmacy, academia, industry, and research. Community 
pharmacies provide a range of products (in respect to diabetes 
prescription and nonprescription medication, blood glucose 
meters and testing strips, needles and swabs, dietary supple-
ments) and services (such as medication review, vaccination, 
unit dose dispensing, needle exchange, point of care testing, 
disposal of unwanted medicines, etc).12 Community phar-
macists are considered to be the most accessible health care 
professionals, as no appointments are required to see them, 
and to have the highest level of patient contact. As such, 
they are well placed to play a significant role in the care of 
patients with T2DM.
This review discusses the health care requirements of 
T2DM and the current and future roles of pharmacists in its 
management. For the purposes of the review, papers were 
identified from English language PubMed and ScienceDirect 
databases up until October 2016, and by manually reviewing 
the references for the papers adjudged relevant based on title 
and abstract, and then full paper review. The keywords used 
included diabetes, pharmacist, pharmacy, intervention, gly-
cosylated hemaglobin (HbA1c), improvement, benefit, and 
outcomes. Papers critiqued in this review include original 
research papers, together with systematic reviews and meta-
analyses. The paper aims to provide an overview of the cur-
rent evidence for the role of pharmacists in diabetes care and 
insights into what roles pharmacists may fulfill in the future.
Health care for T2DM patients
The management of those with T2DM should be seen as a 
partnership between the patient and health care professionals, 
in which the latter support the former in self-managing his or 
her disease. Management of every patient should commence 
with a detailed assessment at the initial diagnosis including 
an appraisal of diabetes complications and risk factors for 
complications. This provides the basis for continuing care 
that includes a treatment plan, treatment administration, 
monitoring, and review (Figure 1 and Table 1).1,13–16
Pharmaceutical care is defined as “the responsible pro-
vision of drug therapy for the purpose of achieving definite 
outcomes that improve a patient’s quality of life”.17 It pro-
vides a platform for multidisciplinary collaboration, which 
means that the pharmacist and the doctor (and potentially 
other care providers) join forces to decide on the optimal 
treatment of the patient so as to achieve the outcome the 
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Role of the pharmacist in the management of T2DM
between the pharmacist and the patient is established and 
maintained, and records on patient’s medications and other 
specific information are collected and evaluated. In the case 
of prescription medicines, a therapy plan currently needs to 
be developed involving the doctor and the patient;18 however, 
pharmacists may also provide input here.
Pharmacy-based services for T2DM 
patients
T2DM is one of a number of common complex conditions, 
including asthma, chronic obstructive pulmonary disease 
and heart failure, which require more time and expertise than 
one practitioner can reasonably provide to achieve optimal 
therapeutic outcomes for the patient.1,14 With the development 
of the concept of pharmaceutical care in which pharmacists 
are engaged more widely in patient care,18 the opportunity 
exists for pharmacists to have a greater role in the care of 
patients with T2DM.
Evidence of the benefits of 
pharmacists in the care of T2DM 
patients
Extensive studies worldwide have evaluated the effective-
ness of pharmacy-based interventions in supporting people 
Initial assessment
•  Medical history
•  Physical examination
•  Laboratory evaluation
Treatment plan
•  Individualized treatment targets
•  Individualized treatment plan
-  Diet, exercise, and antidiabetic agents
-  Prevention/treatment of complications
•  Patient education
Treatment administration
•  Medications prepared
•  Appropriate instructions for use are
    provided 
•  Patient educated
Monitoring
•  Monitor compliance to treatment plan
•  Monitor treatment outcomes
•  Monitor adverse treatment effects
•  Monitor patient comprehension and continuing
    educational needs 
Review
•  Review of treatment plan
•  Consider:
-  Adjust treatment plan
-  Adjust education
-  Referral
T2DM patients
Figure 1 Model of care for T2DM in primary care.
Note: Data from references 1 and 13–15.
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Table 1 Processes involved in the care of patients with T2DM
Stage Activity Component
Initial assessment History taking Specific symptoms of glycosuria/hyperglycemic
Predisposition to diabetes, eg, age, family history, obesity, lifestyle issues (eg, smoking, 
diet, alcohol, physical activity, occupation)
Risk factors for complications: personal or family history of cardiovascular disease, 
overweight/obesity, smoking, hypertension, dyslipidemia
Symptoms of complications, eg, cardiovascular symptoms, neurological symptoms, renal 




Psychosocial status, eg, attitudes about illness, expectations, resources – financial, social, 
and emotional
Physical examinations Weight/waist: BMI, waist circumference
Cardiovascular system, eg, blood pressure measurement
eyes, eg, pupil dilation
Feet, eg, skin condition, sensation
Peripheral nerves, eg, sensation
Urinalysis, eg, albumin
Laboratory evaluation Glycemia: HbA1c, BGL
Lipids: LDL-C, HDL-C, total cholesterol, triglycerides
Renal function: plasma creatinine (eGFR), albuminuria
Other tests when necessary
Treatment plan Individualized treatment targets Glycemic control: BGL, HbA1c
Control of risk factors for complications: lipids, blood pressure, BMI, cigarette consumption
Urinary albumin excretion
Physical activity




Patient education Diabetes disease process
Treatment targets
Treatment plan
  Antidiabetic medicines: dosing instructions, use of insulin devices, storage 
requirements, special precautions, and common/important adverse effects
 exercise
 Diet
  Prevention/treatment of complications, eg, foot care, smoking cessation, medications 
for high lipid/blood pressure levels
Monitoring
 SMBG (using glucose meter and interpreting the results)
 Need for regular medical monitoring
Treatment 
administration
Medications prepared Dispensed in accordance with legal requirements
Appropriate instructions provided Prescription labels on directions for use
Ancillary labels (if required)





Prevention/treatment plans for chronic complications
Scheduled medical monitoring
Monitor treatment outcomes Glycemic control: HbA1c, BGL, SMBG
Control of risk factors for complications: lipids, blood pressure, BMI, cigarette consumption
Presence of complications: cardiovascular system, peripheral nerves, renal, eyes, feet
Monitor adverse effects Presence of adverse drug effects
Review Review of treatment plan based on 
monitoring results
Consider treatment plan adjustment
Consider education adjustment
Referral
Note: Data from references 1 and 13–15.
Abbreviations: BGL, blood glucose level; BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, glycosylated hemoglobin; HDL-C, high-density 
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Role of the pharmacist in the management of T2DM
with T2DM. Most of the studies have been conducted in 
developed western countries, particularly the United States 
of America,19–22 although examples can be found around the 
globe including the United Arab Emirates23 and Hong Kong.24 
Fewer studies however have been conducted in low- and 
middle-income countries such as Nigeria,25 Iran,26 India,27,28 
Brazil,29 Thailand,30 Jordon,31 Iraq,32 and Malaysia.33 The 
range of interventions evaluated are indicated in Table 2.
The interventions were measured for their effectiveness 
using the following:
•	 clinical outcomes, such as glycemic control,29,34–43 reduc-
tion of risk factors (such as blood pressure, lipids, and body 
mass index [BMI]),29,35,42–44 medication adherence,34,38,44–46 
screening for complications,43 and drug-related problems 
identified/solved;35,37,38,42,45
•	 humanistic/social outcomes, such as quality of 
life,27,35,36,42,47 satisfaction,42,46 belief,45 knowledge,27,37,38,41,42 
lifestyle changes,44 and self-care activity;47
•	 economic outcomes, such as health costs.42,43
Blenkinsopp and Hassey48 undertook a systematic review 
to evaluate the effect of community pharmacy interventions 
in diabetes (types 1 and 2). They reviewed seven papers, 
three focused on glycemic control, two on adherence, and 
one each on patient knowledge and medication problems. Six 
of the studies demonstrated positive results (Table 3), with 
two being significant. Components of community pharmacy-
based interventions which appeared to contribute to effective-
ness included the following: patient education/consultation 
about their diabetes and its treatment, medications, and life-
style changes; and monitoring/reviewing glycemic control.48 
Since that review, there have been several others which are 
summarized in Table 3. These systematic reviews have cov-
ered the impact of pharmacists in a number of settings from 
hospitals, outpatients clinics, primary (community) health 
centers, and community pharmacy.19–21,49–51 The results of all 
of the systematic reviews demonstrate support for the role 
of pharmacist in diabetes care across the various settings.
Collins et al21 reported that HbA1c levels decreased by 
an average of 0.76% based upon results of 14 trials involv-
ing 2,073 subjects and fasting blood glucose by an average 
1.63 mmol/L based upon results of four trials involving 
589 subjects as compared to control subjects. Aguiar et al19 
undertook a meta-analysis of 22 studies which examined 
the effect of pharmacist interventions on glycemic control 
in T2DM patients. This analysis demonstrated a statistically 
and clinically significant reduction in HbA1c of −0.85% 
(95% confidence interval [CI]: −1.06 to −0.65, P < 0.0001). 
When community pharmacy interventions were compared 
to other outpatient settings, the effect on HbA1c was similar 
(−0.65% vs −0.98%, P = 0.08). Interestingly, overall, the most 
significant effect on HbA1c was seen in those studies in which 
participants’ baseline HbA1c was >9%. Further, the benefit 
derived reduced as the age of the participants increased.19
Likewise, the reviews in Table 3 have demonstrated sta-
tistically significant improvements in other clinical outcomes 
such as reduction in risk factors and improved medication 
adherence. For example, Santschi et al’s20 meta-analysis 
demonstrated significant reductions in both systolic blood 
pressure (SBP) (−6.2 mmHg, 95% CI −7.8 to −4.2) and 
diastolic blood pressure (DBP) (−4.5 mmHg, 95% CI: −6.2 
to −2.8). Six of the 14 studies included in the analysis of 
SBP involved community pharmacies, with three showing 
significant falls of between −5.6 mmHg and −20.05 mmHg. 
Of the two community pharmacy based trials included 
in the same meta-analysis which reported DBP changes, 
both again demonstrated a positive effect, and one of them 
was significant (−3.90 mmHg, 95% CI: −7.18 to −0.62). 


















Lifestyle: physical activity, diet27,42,43
Medication27,34,35
Psychosocial support: patient health 
beliefs34,35
SMBG: blood glucose meters42
Prevention/treatment of 
complications: foot care, 
smoking cessation, hypertension, 
dyslipidemia43
Unspecified42,44,45/customized content 






Review of blood glucose results36,37,42
Physical examination (blood 









Liaison with the prescribing doctor35,42
Referral for patient education42,44
Referral to a specialist nurse44
Referral for medical advice35,37,44
Abbreviations: HbA1c, glycosylated hemoglobin; SMBG, self-monitoring of blood 








































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





 Significant reductions were also reported for total cholesterol, 
low-density lipoprotein cholesterol, and BMI.
Despite significant variations in the methods by which 
adherence was measured, pharmacist interventions were 
generally shown to have a positive effect, although it was 
unclear in many instances what impact the improvement had 
on clinical outcomes.50 Patients’ knowledge of their disease 
and its complications, its treatment (pharmacological and 
non-pharmacological), and self-monitoring has also been 
shown to be increased through pharmacist-delivered educa-
tional interventions.51
The ability to demonstrate improvements in the quality 
of life of people with diabetes is often hampered by the short 
duration of the studies, and the tools chosen. Despite these 
factors, pharmacist-managed interventions again showed 
positive benefits. Limited studies have investigated the eco-
nomic benefits of pharmacist interventions in diabetes care. 
A recent meta-analysis by Wang et al,22 which included 25 
studies, reported that “pharmacist-managed services had 
a positive return in terms of economic viability”. Ten of 
the 25 studies were completed in community pharmacy. 
Benefits demonstrated included that the average cost of a 
1% reduction in HbA1c was US$174 per person; such a 
reduction translates into a 21% reduction in macrovascular 
complications. Further, whilst pharmacist interventions often 
increased medication costs, these costs were offset by a reduc-
tion in medical costs associated with emergency department 
attendances and hospitalization.22 In fact, compared to usual 
care, pharmacist-led services produced cost savings in the 
range of US$8 to $85,000 per year, whilst costing between 
US$62,803 and US$114,576 to prevent one diabetes-related 
macrovascular and microvascular event. Of the six studies 
that included cost–benefit analysis (cost-to-benefit ratio 
range 1:1–8.5:1), the three that were community pharmacy 
based were either cost neutral (1:1)52 or cost effective (6.1:153 
and 8.5:154). Hendrie et al55 evaluated the economic benefit 
of reduced glycemic events (hypo- and hyperglycemia) in 
a group of patients who enrolled into a 6-month Diabetes 
Management Education Program (DMEP). They found that 
the intervention resulted in significantly greater reductions 
in the number of hyper- and hypoglycemic events relative to 
the control group (odds ratio [OR] 0.34, 95% CI 0.22–0.52, 
P = 0.001 vs OR 0.54, 95% CI 0.34–0.86, P = 0.009). This 
reduction translated into a net reduction of 1.86 days with 
glycemic episodes per patient per month. In terms of cost-
effectiveness, the DMEP costs AU$43 (US$39) per day of 
glycemic symptoms avoided relative to standard care.
In summary, to date, pharmacist interventions to improve 
the care of patients with diabetes, and in particular those with 
T2DM, have been shown to deliver positive clinical, humanis-
tic, and economic benefits. However, the interventions, which 
are often multifaceted, have varied across studies, although 
often education- and clinical review-based, making it difficult 
to determine which elements deliver the greatest benefits.
Future roles for pharmacists in T2DM 
management
To date, evidence supports pharmacists extending their 
role in diabetes care from medication supply to cognitive 
services which aim to assist those with diabetes achieve the 
best possible clinical outcomes through supporting their 
self-management. Realistically, pharmacists potentially have 
a role to play in all facets of the care of T2DM patients as 
depicted in Figure 1. However, widespread implementation 
of such services in the future will depend on legislative 
change, adequate funding (government and nongovernment), 
professional commitment, interprofessional collaboration, 
and consumer (patient) acceptance.
The importance of the latter should not be underesti-
mated, with recent work again illustrating that consumers do 
not perceive community pharmacies as a place to go to get 
assistance with their diabetes care. Consumers are happy to 
accept that pharmacists can provide them with medications 
and counseling; however, they have consistent concerns 
about the knowledge and competency of pharmacists to 
provide additional services, and that community pharmacies 
are a suitable environment to deliver them.56 The findings 
of Dhippayom and Krass57 support this, with participants 
in their study highlighting the main role of pharmacists is 
medication provision, with some enhancements in supporting 
adherence and continuity of supply. Therefore, for commu-
nity pharmacy-based services to succeed, these perceptions 
must be changed; this will require action from within the 
pharmacy profession through further training, establish-
ment of private consulting areas, changes to workflows, and 
proactively promoting pharmacists’ capability to deliver 
enhanced diabetes care.
Delivery of such services within other settings such as 
hospitals, outpatient clinics, and community-based clinics 
is likely to be better received by patients, with pharmacists 
being seen more as a care provider than a supplier of medi-
cines. Evidence supports pharmacists working in these set-
tings, either directing care or collaborating in care.20
Targeting of services to those at greatest need would 
seem appropriate, such as patients with newly diagnosed 
diabetes56 who are often overwhelmed by the diagnosis and 
have a poor understanding of its management. For example, 
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Role of the pharmacist in the management of T2DM
for patients starting oral hypoglycemics, and community 
pharmacists are well placed to fulfill this role. Further, the 
evidence suggests that patients with poorly managed diabetes, 
that is, those with HbA1c > 9 mmol/L,19 gain the greatest 
benefit from pharmacist interventions, suggesting targeting 
such patients would be appropriate. This could be facilitated 
through referrals from medical practitioners or pharmacists 
ordering of HbA1c levels or point-of-care testing.
Funding to deliver pharmacy-based cognitive services is 
a contentious issue, and whilst they can be funded through 
a user-pays model, government-funded or third-party payer 
models are likely to be needed for widespread implementa-
tion of such services. For example, depending on the level of 
remuneration, one would envisage that a limited number of 
community pharmacies specializing in diabetes would offer 
extended services. Legislative change to allow pharmacists 
to manage patients’ diabetes therapy either in consultation 
with their primary health provider or independently, which 
has occurred in some jurisdictions, will allow pharmacists 
delivering such services to have greater impact.
Diabetes screening is another area of significant need 
which pharmacists should engage in as many people liv-
ing with the disease are undiagnosed. A large-scale trial 
is about to commence in Australia to evaluate community 
pharmacists’ role in diabetes screening. This study builds 
upon the work of Krass et al,58 which demonstrated that a 
sequential screening program, that is, tick test followed by 
capillary blood glucose testing, was an effective means to 
detect prediabetic and diabetic patients.
Conclusion
There is significant evidence to support the role of pharmacists 
in providing a range of extended diabetes care services, from 
the screening to ongoing disease state management. However, 
despite this, the provision of such services generally remains 
limited and inconsistent. However, this is set to change, as 
the number of people with T2DM grows, and the capacity of 
traditional care providers to cope with these people dimin-
ishes. Governments, third-party payers, and consumers will 
all be looking for cost-effective ways to manage diabetes. 
Pharmacists are ideally placed to assist patients with their 
diabetes management within a range of clinical settings as 
demonstrated by current evidence. Needed now are models 
of practice which are evidence based, consistent, and scalable, 
such that they deliver the outcomes desired by all stakeholders.
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